Cargando…
BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age
Vaccinations are the most important intervention for controlling the ongoing coronavirus disease (COVID-19) pandemic, caused by the SARS-CoV-2 virus. BNT162b2 is an mRNA-based vaccine, which is promising and safe for use during pregnancy, as it could help prevent SARS-CoV-2 infection and its complic...
Autores principales: | Mangat, Chetna, Milosavljevic, Natasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526266/ https://www.ncbi.nlm.nih.gov/pubmed/34676123 http://dx.doi.org/10.1155/2021/6901131 |
Ejemplares similares
-
Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months
por: Merdrignac, Lore, et al.
Publicado: (2022) -
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
por: Campo, Flaminia, et al.
Publicado: (2021) -
A Rare Case Report of NEHI in a Preterm Infant with Review of the Literature
por: Mangat, Chetna, et al.
Publicado: (2022) -
Antibody titres decline 3-month post-vaccination with BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021) -
Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants
por: Danino, Dana, et al.
Publicado: (2023)